Open Access
Review
The Hippo Signaling Pathway as a Drug Target in Familial Dilated Cardiomyopathy
Paulina Langa1
Beata M. Wolska1, 2
R. John Solaro1, *
Author Information
Submitted: 1 Nov 2022 | Accepted: 24 Nov 2022 | Published: 21 Dec 2022

Abstract

We focus here on the Hippo pathway in the hierarchical sensing and modulation of the mechanical state of the adult heart in health and disease. The Hippo pathway interrogates the micro-environment of cardiac myocytes providing surveillance of the mechanical state with engagement of signaling pathways critical to homeostasis of cardiac development, remodeling, and function and vulnerable to pathologies. Our discussion centers on Hippo signaling in the altered mechanical state instigated by variants of genes expressing mutant sarcomere proteins that trigger a progression to dilated cardiomyopathy (familial DCM). There is an unmet need for therapies in DCM. Recent progress in the discovery of small molecules that target Hippo signaling and are intended for use in cardiac disorders provides leads for modifying Hippo in DCM. As we emphasize, identifying useful targets in DCM requires in depth understanding of cell specific Hippo signaling in the cardiac micro-environment.

Graphical Abstract

References

Share this article:
Graphical Abstract
How to Cite
Langa, P., Wolska, B. M., & Solaro, R. J. (2022). The Hippo Signaling Pathway as a Drug Target in Familial Dilated Cardiomyopathy. International Journal of Drug Discovery and Pharmacology, 1(1), 4. https://doi.org/10.53941/ijddp.v1i1.189
RIS
BibTex
Copyright & License
article copyright Image
R. John Solaro, Beata M. Wolska, Paulina Langa

This work is licensed under a This work is licensed under a Creative Commons Attribution 4.0 International License.

scilight logo

About Scilight

Contact Us

Level 19, 15 William Street, Melbourne, Victoria 3000, Australia
General Inquiries: info@sciltp.com
© 2025 Scilight Press Pty. Ltd. All rights reserved.